TNFSF11 and granular cell tumor: Additional adjuvant therapeutic options are available for the use in patients with unresectable or metastatic disease; and include blocking of the receptor activator of NF-kappa B ligand (RANKL) signaling pathway, which plays a role in the pathogenesis of GCT of bone, via the anti-RANKL monoclonal antibody denosumab.